Advanced Therapeutics最新文献_第9页

Malaria Chemotherapeutics What Next for Africa 疟疾化疗：非洲的下一步是什么

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-03-05 DOI: 10.1002/adtp.202400453

Lucy Ochola, Jesse Gitaka, Bernard Kanoi, Clare Njoki Kimani, Hoseah M. Akala, Martin Omondi Alfred, Lynette Isabella Ochola-Oyier, Bernhards Ogutu

{"title":"Malaria Chemotherapeutics What Next for Africa","authors":"Lucy Ochola, Jesse Gitaka, Bernard Kanoi, Clare Njoki Kimani, Hoseah M. Akala, Martin Omondi Alfred, Lynette Isabella Ochola-Oyier, Bernhards Ogutu","doi":"10.1002/adtp.202400453","DOIUrl":"10.1002/adtp.202400453","url":null,"abstract":"Malaria remains a significant health challenge in sub-Saharan Africa, accounting for 90% of the global burden of disease. Recent studies have reported an increase in the number of malaria cases and a decrease in deaths. However, these gains can be reversed by emerging resistance to artemisinin and changing climatic conditions. Over the past 30 years, Africa has adopted artemisinin combination therapy (ACT) to treat uncomplicated malaria. Increasingly, reports of parasitic mutations conferring tolerance to artemisinin have emerged in several countries, particularly in East Africa. Although markers of resistance to various partner drugs are known, the potential failure of artemisinin can rapidly alter the situation, especially as the Kelch 13 gene, which confers resistance to artemisinin, becomes less conserved. It is anticipated that there will be a need to switch from current ACTs to new combinations or create a framework for multiple first-line deployment. However, this poses challenges ranging from timely review of policies, training of healthcare workers, access, and deployment to the most peripheral health facilities in remote areas. This review outlines several critical factors that can potentially influence decision making in this new paradigm shift, including insufficient funding and challenges in the development of pharmaceutical products.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 4","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoconjugate Improves Cognitive Deficit and Limits the Pathogenic Tau Burden in Okadaic-Acid-Induced Alzheimer's Mice 纳米缀合物改善冈田酸诱导的阿尔茨海默病小鼠的认知缺陷并限制致病性Tau负担

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-03-03 DOI: 10.1002/adtp.202400462

Qiuju Liang, Shoubo Xiang, Pengzhen Wang, Lian Chen, Hongyi Cao, Cheng Tian, Tingting Jiang, Hua Zuo, Zhen Tian, Sanjib Bhattacharyya

{"title":"Nanoconjugate Improves Cognitive Deficit and Limits the Pathogenic Tau Burden in Okadaic-Acid-Induced Alzheimer's Mice","authors":"Qiuju Liang, Shoubo Xiang, Pengzhen Wang, Lian Chen, Hongyi Cao, Cheng Tian, Tingting Jiang, Hua Zuo, Zhen Tian, Sanjib Bhattacharyya","doi":"10.1002/adtp.202400462","DOIUrl":"10.1002/adtp.202400462","url":null,"abstract":"Alzheimer's disease (AD) is characterized by a progressive loss of cognition and its distinct hyperphosphorylated Tau (p-tau) pathology. Both insulin resistance(IRT) and p-tau share a causal relationship in AD, whereas the connective mechanism between them remains largely unknown. Tau protein is considered the primary target to combat AD as loss of Tau function triggers neuronal loss in AD. In the prior report, it is observed that self-therapeutic gold nanoparticles alleviate Tauopathy in models of AD. Gold nanoparticles (AuNPs)─polyethylene glycol 2000 (PEG2000)─transferrin (Tf) nanoconjugate is synthesized for passive targeting to pharmacologically regulate neuronal tau. It is observed that AuNPs─PEG2000─Tf decreases p-tau while restores insulin receptor(IR) and activates protein kinase B (AKT) kinase in SHSY5Y cell overexpressing Tau. AuNPs─PEG2000─Tf downregulates transferrin receptor by inhibiting recombinant divalent metal transporter 1 protein, affecting Fe2+ accumulation. AuNPs─PEG2000─Tf improves learning ability of mice in okadaic-acid-induced, stereotaxic model in a dose-dependent fashion compared to memantine and subsequently decreases both p-tau and acetyl tau levels and upregulates the AKT signal. Changes in p-tau/Tau index from mouse brain homogenate is diminished following AuNPs─PEG2000─Tf treatment as a desired therapeutic outcome. Given AuNPs─PEG2000─Tf treatment restricts pathogenic conversion of Tau (p-tau, acetyl Tau), further investigation is warranted to bridge the connection between gold-nanoparticle-mediated alteration of IRT and AD progression.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400462","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanotechnology in Gene Editing: Pioneering CRISPR-Cas Delivery Systems to Tackle Antibiotic Resistance 纳米技术在基因编辑：开拓CRISPR-Cas传递系统，以解决抗生素耐药性

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-03-03 DOI: 10.1002/adtp.202400412

Sahar Gholamian, Pooya Baghaee, Mohammad Doroudian

{"title":"Nanotechnology in Gene Editing: Pioneering CRISPR-Cas Delivery Systems to Tackle Antibiotic Resistance","authors":"Sahar Gholamian, Pooya Baghaee, Mohammad Doroudian","doi":"10.1002/adtp.202400412","DOIUrl":"10.1002/adtp.202400412","url":null,"abstract":"The rise of antibiotic-resistant bacteria, driven by antibiotic misuse, is a major global health threat. Addressing this issue requires understanding resistance mechanisms and developing innovative solutions. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated systems (Cas), a genome-editing tool derived from prokaryotic defense mechanisms, offers precise targeting of antibiotic-resistant genes. By reprogramming CRISPR-Cas, bacteria can be killed or resensitized to antibiotics through plasmid curing. However, clinical applications face challenges, particularly in delivering CRISPR-Cas components effectively. Nanotechnology has emerged as a promising approach for targeted delivery to tissues and cells. This paper explores the molecular mechanisms of antibiotic resistance, emphasizing the structure and function of CRISPR-Cas systems and their delivery mechanisms. It highlights the use of nanoparticles (NPs) and nanoscale carriers to deliver CRISPR-Cas components, reviewing recent studies that combine NPs and CRISPR to target resistance genes. Additionally, the paper discusses current challenges and future prospects in this field, underscoring the potential of CRISPR-Cas and nanotechnology to combat antibiotic resistance.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Vitro and In Vivo Therapeutics of Double-Layered Hydrogels 双层水凝胶的体外和体内治疗

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-02-25 DOI: 10.1002/adtp.202400266

Shikha Awasthi

{"title":"In Vitro and In Vivo Therapeutics of Double-Layered Hydrogels","authors":"Shikha Awasthi","doi":"10.1002/adtp.202400266","DOIUrl":"10.1002/adtp.202400266","url":null,"abstract":"Double-layered hydrogels are organized into different nanostructured layers and are the preferred material for various in vitro and in vivo therapeutic applications. Hydrogels are extensively employed in several domains, such as water treatment and biomedicine. Because of hydrogels' unique potentials like their tissue resemblance and ease of processing, significant progress is achieved in these domains. However, based on a thorough examination of hydrogel microstructures, it is difficult for conventional homogeneous hydrogels to concurrently address various demands due to the growth of in vitro and in vivo necessities in controlled drug delivery, cartilage repair, cell encapsulation, and other utilities. Thankfully, research on heterogeneous dual-layered hydrogels has developed and is now a remarkable area of hydrogel engineering. This review abridged the current developments in multi-layered hydrogels according to their structural design, fabrication techniques, and recent experimental findings along with special attention to the therapeutic applications of double-layered hydrogels. The report concluded by discussing the challenges in the design of double-layered hydrogels and pointed out a new direction of 3D printing, which may offer a new approach to designing double-layered hydrogels and expand the range of in vitro and in vivo therapeutic studies.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applications of Nanomaterial-Microorganism Hybrid Systems in the Treatment of Tumor 纳米材料-微生物混合系统在肿瘤治疗中的应用

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-02-21 DOI: 10.1002/adtp.202400425

Muskan Saif Khan, Mirza Albash Baig, Meng Tian, Bowen Li, Guoqing Feng, Run Yang, Yang Bai, Bin Zheng

{"title":"Applications of Nanomaterial-Microorganism Hybrid Systems in the Treatment of Tumor","authors":"Muskan Saif Khan, Mirza Albash Baig, Meng Tian, Bowen Li, Guoqing Feng, Run Yang, Yang Bai, Bin Zheng","doi":"10.1002/adtp.202400425","DOIUrl":"10.1002/adtp.202400425","url":null,"abstract":"Recent advances in cancer treatments such as targeted therapy and immunotherapy, have brought hope for curing a variety of cancers. However, there are ongoing challenges such as poor targeting, biocompatibility and biosafety. Engineered bacteria can cope with these problems, providing a unique therapeutic approach for the treatment of tumors. Nanotechnology offers the potential to modify the surface of bacteria, and the use of biofilm and coating technology to physically encapsulate bacteria can help bacteria escape the host immune system and improve the efficiency and safety of drug delivery. Synthetic biology and genetic engineering technologies can treat bacteria as “robotic factories” to produce and deliver anti-cancer drugs, including anti-tumor cytokines, immunomodulators, prodrug enzymes, and so on, according to clinical needs. Engineered bacteria therapies can be used either as monotherapy or in combination with other anticancer therapies to achieve better clinical outcomes. In this review, it introduce and summarize the processing and modification methods of engineered bacteria for cancer targeted therapy, and summarize and analyze the current clinical trials of engineered bacteria for cancer targeted therapy.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Self-Assembled Nanocarriers of Synthetic and Natural Plasmalogens for Potential Nanomedicine Development (Adv. Therap. 2/2025) 用于潜在纳米药物开发的合成和天然缩醛原自组装纳米载体（Adv. therapy . 2/2025）

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-02-13 DOI: 10.1002/adtp.202570004

Yu Wu, Borislav Angelov, Yuru Deng, Takehiko Fujino, Md Shamim Hossain, Thomas Bizien, Angelina Angelova

引用次数: 0

Issue Information (Adv. Therap. 2/2025) 发行信息（ad . therapy . 2/2025）

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-02-13 DOI: 10.1002/adtp.202570005

引用次数: 0

Photothermal Therapy: From Encouraging Lab Results to Lackluster Clinical Translation 光热疗法：从令人鼓舞的实验室结果到平淡的临床转化

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-02-09 DOI: 10.1002/adtp.202400347

Jonathan Buiel, Jordan Robert, Dikran Mekhjian, Deepak S. Chauhan, Xavier Banquy

{"title":"Photothermal Therapy: From Encouraging Lab Results to Lackluster Clinical Translation","authors":"Jonathan Buiel, Jordan Robert, Dikran Mekhjian, Deepak S. Chauhan, Xavier Banquy","doi":"10.1002/adtp.202400347","DOIUrl":"10.1002/adtp.202400347","url":null,"abstract":"Cancer is a pervasive and complex disease that poses a significant threat to public health worldwide. The prevalent therapeutic options, including chemotherapy and radiotherapy, pose detrimental side effects. Consequently, non-invasive and selective therapeutic strategies are sought, such as nanoparticle-mediated photothermal therapy (PTT). This technique employs benign photothermal agents that gather within tumors post-injection. Under near-infra-red light exposure, these agents induce localized hyperthermia, killing tumor cells. Here, the laboratory development, recent advances, and clinical status of photothermal therapy are examined. Despite two decades of development, photothermal therapy has yielded few clinical trials. A standout agent, the gold nanoshell, holds promise for prostate cancer treatment as the only one in human clinical trials. To provide context, PTT is compared to photodynamic therapy, which has over 250 human trials in 40 years, highlighting the need to bridge the gap for effective photothermal therapy translation. Therefore, we delve into the gap of clinical implementation between photothermal therapy and similar technologies, such as photodynamic therapy, laser interstitial thermal therapy, and cancer nanomedicines, offering insights and potential solutions.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineering Eutectogel Microneedle Patch as Effective Transdermal Delivery System of Hydrophobic Drugs 工程共tectol微针贴剂作为疏水药物的有效透皮给药系统

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-02-09 DOI: 10.1002/adtp.202400521

Danilo M. dos Santos, Hasika Suresh, Samantha J. Kruzshak, Jihyun Kim, Peggy Cebe, James D. Baleja, Emmanuel S. Tzanakakis, Sameer Sonkusale

{"title":"Engineering Eutectogel Microneedle Patch as Effective Transdermal Delivery System of Hydrophobic Drugs","authors":"Danilo M. dos Santos, Hasika Suresh, Samantha J. Kruzshak, Jihyun Kim, Peggy Cebe, James D. Baleja, Emmanuel S. Tzanakakis, Sameer Sonkusale","doi":"10.1002/adtp.202400521","DOIUrl":"10.1002/adtp.202400521","url":null,"abstract":"Conventional drug delivery methods often face challenges in terms of patient adherence and drug administration. Microneedles (MNs) patches have emerged as a promising alternative, offering a minimally invasive transdermal route for medications. However, their drug-loading capacity remains limited, particularly for hydrophobic active pharmaceutical ingredients (APIs). Herein, microneedles are designed based on eutectic solvent gels (eutectogels) as transdermal carriers for hydrophobic APIs. A natural deep eutectic solvent (NADES) is combined to enhance the solubility of the hydrophobic APIs within the GelMA/PEGDA matrix for mechanical strength and sustained release from the resulting eutectogels microneedles (EU-MNs). Using docetaxel, 5-fluorouracil, and curcumin as hydrophobic APIs models, the superior drug-loading capacity of the EU-MNs is demonstrated. In vitro experiments revealed that the EU-MNs provided a sustained release of distinct hydrophobic APIs over 4 days. Additionally, by properly adjusting the concentration and type of APIs, these microneedle patches do not exhibit cytotoxic effects on fibroblasts cell line (NIH/3T3), underscoring their potential for safe and effective transdermal drug delivery. These findings highlight the potential of EU-MNs as versatile, eco-friendly transdermal vehicles for large amounts of hydrophobic APIs, leading to more effective treatments for these drugs.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Copper Ions in Mediating the Anti-Cancer Effects Using Nanomaterials 铜离子在纳米材料抗癌中的作用

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-02-03 DOI: 10.1002/adtp.202400426

Irfan Mehmud, Song Wu, Shaohua Zhang

{"title":"The Role of Copper Ions in Mediating the Anti-Cancer Effects Using Nanomaterials","authors":"Irfan Mehmud, Song Wu, Shaohua Zhang","doi":"10.1002/adtp.202400426","DOIUrl":"10.1002/adtp.202400426","url":null,"abstract":"Copper plays a pivotal role in human physiology, particularly in oncology, acting both as a facilitator of progression and also as a potential avenue for advanced therapeutic approaches. Maintaining copper homeostasis is crucial. The dysregulation of copper homeostasis is implicated in tumor growth through its involvement in critical processes of angiogenesis, proliferation, and metastasis. The elevation in copper level in the tumor microenvironment (TME) activates oncogenic pathways to drive the neovascularization and sustained growth of malignancies. However, the same reliance on copper offers a unique weakness that can be leveraged for innovative therapeutic interventions. The recent advances in nanomedicine enable the synthesis of nanostructures that can help modulate the level of copper with precision offering multifaceted approaches for copper-based cancer therapy with controlled release mechanism, optimized structures to induce cuproptosis, selective eradication of cancer cells with minimum and systemic toxicity. This review explores the dual role of copper in cancer biology, emphasizing its contribution to the progression of tumors and its emerging application in targeted cancer therapy. The review also highlights the potential of nanostructures in harnessing copper-based therapies and their transformative potential from bench to bed side with novel, highly effective, and clinical safety.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0